

Short Curriculum Vitae

Marcie Glicksman

Marcie Glicksman, Ph.D. is the Co-Director of the Laboratory for Drug Discovery in Neurodegeneration (LDDN) which is focused on accelerating the identification of new therapeutics for central nervous system diseases. Dr. Glicksman has extensive experience in assay development, high throughput screening, as well as animal pharmacology and preclinical development. She has been in the field of drug discovery for more than 20 years, the most recent nine years at LDDN and thirteen years in the pharmaceutical industry. Previously, she was at the company, Descartes Therapeutics focused on pain therapeutics and Cubist focused on anti-infectives. Prior to these positions, she was at DuPont-Merck and at Cephalon, Inc. She has led multiple advanced programs for neurodegenerative diseases including co-inventorship of CEP1347, a drug candidate directed at a kinase that has been in Phase III clinical trials. She was elected (2005-2009) to the Board of Directors and served as Chairman of the Society for Biomolecular Sciences (now Society for Laboratory Automation and Screening). She is on the science advisory board for the Alzheimer's disease foundation (ADDF/ISOA) and the California Institute for Regenerative Medicine (CIRM), and reviews grants for NIH, the Michael J Fox, Alzheimer's Association, and Rett Foundations. Dr. Glicksman co-founded the Academic Drug Discovery Consortium with three colleagues as a way to build a collaborative network for the academic drug discovery community. She also regularly consults and this has included filing an Investigational New Drug application with the FDA, as well as projects involving the development of new technologies. Dr. Glicksman received a bachelor's degree from Brown University and a Ph.D. degree in Neuroscience from Washington University.

List of publications:

Glicksman MA. The 14th international conference on Alzheimer's drug discovery, 9 - 10 september 2013, in jersey city, new jersey. Expert Opin Drug Discov. 2014 Feb; 9(2):215-20.

Slusher BS, Conn PJ, Frye S, Glicksman M, Arkin M. Bringing together the academic drug discovery community. Nat Rev Drug Discov. 2013 Oct 31; 12(11):811-2.

Boyd JD, Lee-Armandt JP, Feiler MS, Zaarur N, Liu M, Kraemer B, Concannon JB, Ebata A, Wolozin B, Glicksman MA. A High-Content Screen Identifies Novel Compounds That Inhibit Stress-Induced TDP-43 Cellular Aggregation and Associated Cytotoxicity. J Biomol Screen. 2014 Jan; 19(1):44-56.

Cherry JJ, Osman EY, Evans MC, Choi S, Xing X, Cuny GD, Glicksman MA, Lorson CL, Androphy EJ. Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds. *EMBO Mol Med*. 2013 Jul; 5(7):1103-18.

Liu M, Bender SA, Cuny GD, Sherman W, Glicksman M, Ray SS. Type II Kinase Inhibitors Show an Unexpected Inhibition Mode against Parkinson's Disease-Linked LRRK2 Mutant G2019S. *Biochemistry*. 2013 Mar 12; 52(10):1725-36.

Glicksman M, Pajak L, Lam K. Stem cell themes: promises and challenges. *J Biomol Screen*. 2012 Oct; 17(9):E1-3.

Abraham CR, Chen C, Cuny GD, Glicksman MA, Zeldich E. Small-molecule Klotho enhancers as novel treatment of neurodegeneration. *Future Med Chem*. 2012 Sep; 4(13):1671-9.

Lin CL, Kong Q, Cuny GD, Glicksman MA. Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases. *Future Med Chem*. 2012 Sep; 4(13):1689-700.

Wright PD, Wightman N, Huang M, Weiss A, Sapp PC, Cuny GD, Iverson AJ, Glicksman MA, Ferrante RJ, Matson W, Matson S, Brown RH. A high-throughput screen to identify inhibitors of SOD1 transcription. *Front Biosci (Elite Ed)*. 2012; 4:2801-8.

Costa SC, Schmitz AM, Jahufar FF, Boyd JD, Cho MY, Glicksman MA, Lesser CF. A new means to identify type 3 secreted effectors: functionally interchangeable class IB chaperones recognize a conserved sequence. *MBio*. 2012; 3(1).

Cuny GD, Ulyanova NP, Patnaik D, Liu JF, Lin X, Auerbach K, Ray SS, Xian J, Glicksman MA, Stein RL, Higgins JM. Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors. *Bioorg Med Chem Lett*. 2012 Mar 1; 22(5):2015-9.

Cherry JJ, Evans MC, Ni J, Cuny GD, Glicksman MA, Androphy EJ. Identification of novel compounds that increase SMN protein levels using an improved SMN2 reporter cell assay. *J Biomol Screen*. 2012 Apr; 17(4):481-95.

King GD, Chen C, Huang MM, Zeldich E, Brazee PL, Schuman ER, Robin M, Cuny GD, Glicksman MA, Abraham CR. Identification of novel small molecules that elevate Klotho expression. *Biochem J*. 2012 Jan 1; 441(1):453-61.

So PP, Zeldich E, Seyb KI, Huang MM, Concannon JB, King GD, Chen CD, Cuny GD, Glicksman MA, Abraham CR. Lowering of amyloid beta peptide production with a small molecule inhibitor of amyloid- β precursor protein dimerization. *Am J Neurodegener Dis*. 2012; 1(1):75-87.

Tang X, Seyb KI, Huang M, Schuman ER, Shi P, Zhu H, Glicksman MA. A high-throughput screening method for small-molecule inhibitors of the aberrant mutant SOD1 and dynein complex interaction. *J Biomol Screen*. 2012 Mar; 17(3):314-26.

Hart MJ, Glicksman M, Liu M, Sharma MK, Cuny G, Galvan V. Development of a high-throughput screen targeting caspase-8-mediated cleavage of the amyloid precursor protein. *Anal Biochem*. 2012 Feb 15; 421(2):467-76.

Glicksman MA. The preclinical discovery of amyotrophic lateral sclerosis drugs. *Expert Opin Drug Discov.* 2011 Nov; 6(11):1127-38.

Liu M, Kang S, Ray S, Jackson J, Zaitsev AD, Gerber SA, Cuny GD, Glicksman MA. Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant. *Biochemistry.* 2011 Nov 1; 50(43):9399-408.

Wilkinson K, Boyd JD, Glicksman M, Moore KJ, El Khoury J. A high content drug screen identifies ursolic acid as an inhibitor of amyloid beta protein interactions with its receptor CD36. *J Biol Chem.* 2011 Oct 7; 286(40):34914-22.

Xing X, Chang LC, Kong Q, Colton CK, Lai L, Glicksman MA, Lin CL, Cuny GD. Structure-activity relationship study of pyridazine derivatives as glutamate transporter EAAT2 activators. *Bioorg Med Chem Lett.* 2011 Oct 1; 21(19):5774-7.

Garkavtsev I, Chauhan VP, Wong HK, Mukhopadhyay A, Glicksman MA, Peterson RT, Jain RK. Dehydro-alpha-lapachone, a plant product with antivasular activity. *Proc Natl Acad Sci U S A.* 2011 Jul 12; 108(28):11596-601.

Shishova EY, Stoll JM, Ersoy BA, Shrestha S, Scapa EF, Li Y, Niepel MW, Su Y, Jelicks LA, Stahl GL, Glicksman MA, Gutierrez-Juarez R, Cuny GD, Cohen DE. Genetic ablation or chemical inhibition of phosphatidylcholine transfer protein attenuates diet-induced hepatic glucose production. *Hepatology.* 2011 Aug; 54(2):664-74.

Cullen V, Sardi SP, Ng J, Xu YH, Sun Y, Tomlinson JJ, Kolodziej P, Kahn I, Saftig P, Woulfe J, Rochet JC, Glicksman MA, Cheng SH, Grabowski GA, Shihabuddin LS, Schlossmacher MG. Acid β -glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α -synuclein processing. *Ann Neurol.* 2011 Jun; 69(6):940-53.

Wright PD, Huang M, Weiss A, Matthews J, Wightman N, Glicksman M, Brown RH. Screening for inhibitors of the SOD1 gene promoter: pyrimethamine does not reduce SOD1 levels in cell and animal models. *Neurosci Lett.* 2010 Oct 4; 482(3):188-92.

Cuny GD, Robin M, Ulyanova NP, Patnaik D, Pique V, Casano G, Liu JF, Lin X, Xian J, Glicksman MA, Stein RL, Higgins JM. Structure-activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors. *Bioorg Med Chem Lett.* 2010 Jun 15; 20(12):3491-4.

Liu M, Girma E, Glicksman MA, Stein RL. Kinetic mechanistic studies of Cdk5/p25-catalyzed H1P phosphorylation: metal effect and solvent kinetic isotope effect. *Biochemistry.* 2010 Jun 15; 49(23):4921-9.

Liu M, Poulouse S, Schuman E, Zaitsev AD, Dobson B, Auerbach K, Seyb K, Cuny GD, Glicksman MA, Stein RL, Yue Z. Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors. *Anal Biochem.* 2010 Sep 15; 404(2):186-92.

Colton CK, Kong Q, Lai L, Zhu MX, Seyb KI, Cuny GD, Xian J, Glicksman MA, Lin CL. Identification of translational activators of glial glutamate transporter EAAT2 through cell-based high-

throughput screening: an approach to prevent excitotoxicity. *J Biomol Screen.* 2010 Jul; 15(6):653-62.

Kuohung W, Burnett M, Mukhtyar D, Schuman E, Ni J, Crowley WF, Glicksman MA, Kaiser UB. A high-throughput small-molecule ligand screen targeted to agonists and antagonists of the G-protein-coupled receptor GPR54. *J Biomol Screen.* 2010 Jun; 15(5):508-17.

Ouertatani-Sakouhi H, Liu M, El-Turk F, Cuny GD, Glicksman MA, Lashuel HA. Kinetic-based high-throughput screening assay to discover novel classes of macrophage migration inhibitory factor inhibitors. *J Biomol Screen.* 2010 Apr; 15(4):347-58.

Liu M, Dobson B, Glicksman MA, Yue Z, Stein RL. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities. *Biochemistry.* 2010 Mar 9; 49(9):2008-17.

Qiao L, Choi S, Case A, Gainer TG, Seyb K, Glicksman MA, Lo DC, Stein RL, Cuny GD. Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors. *Bioorg Med Chem Lett.* 2009 Nov 1; 19(21):6122-6.

Patnaik D, Glicksman MA, Cuny GD, Stein RL, Higgins JM. Identification of small molecule inhibitors of the mitotic kinase haspin by high-throughput screening using a homogeneous time-resolved fluorescence resonance energy transfer assay. *J Biomol Screen.* 2008 Dec; 13(10):1025-34.

Seyb KI, Schuman ER, Ni J, Huang MM, Michaelis ML, Glicksman MA. Identification of small molecule inhibitors of beta-amyloid cytotoxicity through a cell-based high-throughput screening platform. *J Biomol Screen.* 2008 Oct; 13(9):870-8.

Wagle N, Xian J, Shishova EY, Wei J, Glicksman MA, Cuny GD, Stein RL, Cohen DE. Small-molecule inhibitors of phosphatidylcholine transfer protein/StarD2 identified by high-throughput screening. *Anal Biochem.* 2008 Dec 1; 383(1):85-92.

Liu M, Choi S, Cuny GD, Ding K, Dobson BC, Glicksman MA, Auerbach K, Stein RL. Kinetic studies of Cdk5/p25 kinase: phosphorylation of tau and complex inhibition by two prototype inhibitors. *Biochemistry.* 2008 Aug 12; 47(32):8367-77.

Glicksman MA, Cuny GD, Liu M, Dobson B, Auerbach K, Stein RL, Kosik KS. New approaches to the discovery of cdk5 inhibitors. *Curr Alzheimer Res.* 2007 Dec; 4(5):547-9.

Donahue CP, Ni J, Rozners E, Glicksman MA, Wolfe MS. Identification of tau stem loop RNA stabilizers. *J Biomol Screen.* 2007 Sep; 12(6):789-99.

Rossi C, Padmanaban D, Ni J, Yeh LA, Glicksman MA, Waldner H. Identifying druglike inhibitors of myelin-reactive T cells by phenotypic high-throughput screening of a small-molecule library. *J Biomol Screen.* 2007 Jun; 12(4):481-9.

Broom WJ, Auwarter KE, Ni J, Russel DE, Yeh LA, Maxwell MM, Glicksman M, Kazantsev AG, Brown RH. Two approaches to drug discovery in SOD1-mediated ALS. *J Biomol Screen.* 2006 Oct; 11(7):729-35.

Bandyopadhyay S, Ni J, Ruggiero A, Walshe K, Rogers MS, Chattopadhyay N, Glicksman MA, Rogers JT. A high-throughput drug screen targeted to the 5'untranslated region of Alzheimer amyloid precursor protein mRNA. *J Biomol Screen*. 2006 Aug; 11(5):469-80.

Thompson LA, Liauw AY, Ramanjulu MM, Kasireddy-Polam P, Mercer SE, Maduskuie TP, Glicksman M, Roach AH, Meredith JE, Liu RQ, Combs AP, Higaki JN, Cordell B, Seiffert D, Zaczek RC, Robertson DW, Olson RE. Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. *Bioorg Med Chem Lett*. 2006 May 1; 16(9):2357-63.

Glicksman MA, Chiu AY, Dionne CA, Harty M, Kaneko M, Murakata C, Oppenheim RW, Prevette D, Sengelaub DR, Vaught JL, Neff NT. CEP-1347/KT7515 prevents motor neuronal programmed cell death and injury-induced dedifferentiation in vivo. *J Neurobiol*. 1998 Jun 15; 35(4):361-70.

Borasio GD, Horstmann S, Anneser JM, Neff NT, Glicksman MA. CEP-1347/KT7515, a JNK pathway inhibitor, supports the in vitro survival of chick embryonic neurons. *Neuroreport*. 1998 May 11; 9(7):1435-9.

Maroney AC, Glicksman MA, Basma AN, Walton KM, Knight E, Murphy CA, Bartlett BA, Finn JP, Angeles T, Matsuda Y, Neff NT, Dionne CA. Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. *J Neurosci*. 1998 Jan 1; 18(1):104-11.

Kaneko M, Saito Y, Saito H, Matsumoto T, Matsuda Y, Vaught JL, Dionne CA, Angeles TS, Glicksman MA, Neff NT, Rotella DP, Kauer JC, Mallamo JP, Hudkins RL, Murakata C. Neurotrophic 3,9-bis[(alkylthio)methyl]-and-bis(alkoxymethyl)-K-252a derivatives. *J Med Chem*. 1997 Jun 6; 40(12):1863-9.

Vaught JL, Contreras PC, Glicksman MA, Neff NT. Potential utility of rhIGF-1 in neuromuscular and/or degenerative disease. *Ciba Found Symp*. 1996; 196:18-27; discussion 27-38.

Glicksman MA, Forbes ME, Prantner JE, Neff NT. K-252a promotes survival and choline acetyltransferase activity in striatal and basal forebrain neuronal cultures. *J Neurochem*. 1995 Apr; 64(4):1502-12.

Maroney AC, Lipfert L, Forbes ME, Glicksman MA, Neff NT, Siman R, Dionne CA. K-252a induces tyrosine phosphorylation of the focal adhesion kinase and neurite outgrowth in human neuroblastoma SH-SY5Y cells. *J Neurochem*. 1995 Feb; 64(2):540-9.

Neff NT, Prevette D, Houenou LJ, Lewis ME, Glicksman MA, Yin QW, Oppenheim RW. Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival. *J Neurobiol*. 1993 Dec; 24(12):1578-88.

Bozyczko-Coyne D, Glicksman MA, Prantner JE, McKenna B, Connors T, Friedman C, Dasgupta M, Neff NT. IGF-I supports the survival and/or differentiation of multiple types of central nervous system neurons. *Ann N Y Acad Sci*. 1993 Aug 27; 692:311-3.

Glicksman MA, Prantner JE, Meyer SL, Forbes ME, Dasgupta M, Lewis ME, Neff N. K-252a and staurosporine promote choline acetyltransferase activity in rat spinal cord cultures. *J Neurochem*. 1993 Jul; 61(1):210-21.

Glicksman MA, Brower DL. Persistent ectopic expression of *Drosophila* homeotic genes resulting from maternal deficiency of the extra sex combs gene product. *Dev Biol.* 1990 Dec; 142(2):422-31.

Glicksman MA, Brower DL. Expression of the Sex combs reduced protein in *Drosophila* larvae. *Dev Biol.* 1988 May; 127(1):113-8.

Glicksman MA, Brower DL. Misregulation of homeotic gene expression in *Drosophila* larvae resulting from mutations at the extra sex combs locus. *Dev Biol.* 1988 Apr; 126(2):219-27.

Gauger A, Glicksman MA, Salatino R, Condie JM, Schubiger G, Brower DL. Segmentally repeated pattern of expression of a cell surface glycoprotein in *Drosophila* embryos. *Development.* 1987 Jun; 100(2):237-44.

Glicksman MA, Soppet D, Willard MB. Posttranslational modification of neurofilament polypeptides in rabbit retina. *J Neurobiol.* 1987 Mar; 18(2):167-96.

Glicksman MA, Willard M. Differential expression of the three neurofilament polypeptides. *Ann N Y Acad Sci.* 1985; 455:479-91.

Hirokawa N, Glicksman MA, Willard MB. Organization of mammalian neurofilament polypeptides within the neuronal cytoskeleton. *J Cell Biol.* 1984 Apr; 98(4):1523-36.

Glicksman MA, Sanes JR. Differentiation of motor nerve terminals formed in the absence of muscle fibres. *J Neurocytol.* 1983 Aug; 12(4):661-71.

Baitinger C, Cheney R, Clements D, Glicksman M, Hirokawa N, Levine J, Meiri K, Simon C, Skene P, Willard M. Axonally transported proteins in axon development, maintenance, and regeneration. *Cold Spring Harb Symp Quant Biol.* 1983; 48 Pt 2:791-802.

Glicksman MA, Willard M. Separation of neurofilaments from ATPase activity by precipitation with anti-neurofilament antibodies. *J Neurochem.* 1982 Jun; 38(6):1774-6.

Bizzini B, Grob P, Glicksman MA, Akert K. Use of the B-IIb tetanus toxin derived fragment as a specific neuropharmacological transport agent. *Brain Res.* 1980 Jul 7; 193(1):221-7.

Glicksman MA. Localization of motoneurons controlling the extraocular muscles of the rat. *Brain Res.* 1980 Apr 21; 188(1):53-62.

Akert K, Glicksman MA, Lang W, Grob P, Huber A. The Edinger-Westphal nucleus in the monkey. A retrograde tracer study. *Brain Res.* 1980 Feb 24; 184(2):491-8.

Bizzini B, Akert K, Glicksman M, Grob P. Preparation of conjugates using two tetanus toxin derived fragments: their binding to gangliosides and isolated synaptic membranes and their immunological properties. *Toxicon.* 1980; 18(5-6):561-72.